Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment

Alessandra Trojani, Ester Pungolino, Giuseppe Rossi, Mariella D'Adda, Milena Lodola, Barbara Di Camillo, Alessandra Perego, Mauro Turrini, Ester Orlandi, Lorenza Borin, Alessandra Iurlo, Simona Malato, Francesco Spina, Maria Luisa Latargia, Francesco Lanza, Salvatore Artale, Michela Anghilieri, Maria Cristina Carraro, Gabriella De Canal, Enrica MorraRoberto Cairoli

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder with heterogeneous biological and clinical features. The biomolecular mechanisms of CML response to tyrosine-kinase inhibitors are not fully defined.

OBJECTIVE: We undertook a gene expression profiling (GEP) study of selected bone marrow (BM) CD34+/lin- cells of chronic-phase CML patients at diagnosis and after 12 months of TKI nilotinib to investigate molecular signatures characterizing both conditions.

Original languageEnglish
Pages (from-to)41-53
Number of pages13
JournalCancer Biomarkers
Volume21
Issue number1
DOIs
Publication statusPublished - 2018

Keywords

  • Antigens, CD34/blood
  • Bone Marrow Cells/metabolism
  • Gene Expression Profiling/methods
  • Gene Expression Regulation, Leukemic/drug effects
  • Humans
  • Leukemia, Myeloid, Chronic-Phase/blood
  • Leukocyte Count
  • Protein-Tyrosine Kinases/therapeutic use
  • Pyrimidines/therapeutic use
  • Time Factors
  • Treatment Outcome

Fingerprint Dive into the research topics of 'Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment'. Together they form a unique fingerprint.

Cite this